Stress Echocardiography Study With Regadenoson

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-30

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Regadenoson is approved in the US under the brand name Lexiscan for myocardial perfusion imaging. This study will test whether regadenoson is an appropriate stress agent for stress echocardiography.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Accuracy Study of Regadenoson Atropine Combination for Stress Echocardiography in Identification of Coronary Artery Disease

NCT00894179

Coronary Artery Disease

UNKNOWN

Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

NCT01250496

Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan

TERMINATED PHASE4

Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging

NCT02115308

Coronary Artery Disease

COMPLETED PHASE4

Regadenoson Real Time Perfusion Imaging Trial-Optison

NCT01489176

Coronary Artery Disease Myocardial Perfusion Abnormalities

COMPLETED PHASE3

Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia

NCT01161121

Coronary Artery Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Disease Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Regadenoson alone

Group Type EXPERIMENTAL

regadenoson

Intervention Type DRUG

400 ug, IV

Regadenoson with exercise

Group Type EXPERIMENTAL

regadenoson

Intervention Type DRUG

400 ug, IV

Regadenoson with contrast agent

Group Type EXPERIMENTAL

regadenoson

Intervention Type DRUG

400 ug, IV

Regadenoson with contrast agent (perfusion)

Group Type EXPERIMENTAL

regadenoson

Intervention Type DRUG

400 ug, IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

regadenoson

400 ug, IV

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a clinically indicated dobutamine echocardiogram showing normal wall motion at rest and abnormal wall motion with stress
* Patients with a clinically indicated dipyridamole echocardiogram showing normal perfusion and wall motion at rest and abnormal perfusion with or without abnormal wall motion with stress

Exclusion Criteria

* Any condition precluding the safe administration of dobutamine, dipyridamole or SonoVue for echocardiography
* Pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method of birth control

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No